Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from CardieX ( (AU:CDX) ) is now available.
Cardiex Limited has announced the dispatch of its Entitlement Offer Booklet for a fully underwritten non-renounceable pro rata entitlement offer of new shares. The offer aims to raise approximately $4.1 million before costs, with a closing date set for June 20, 2025. This initiative is expected to strengthen Cardiex’s financial position and support its ongoing efforts in advancing vascular health technologies.
More about CardieX
Cardiex is a company focused on medical technology advancements in vascular health. It offers a range of products including medical and home health devices and digital solutions for hypertension, cardiovascular disease, and other vascular health disorders, leveraging its SphygmoCor® vascular biomarker technology. Cardiex is listed on the Australian Stock Exchange (ASX:CDX).
Average Trading Volume: 245,823
Technical Sentiment Signal: Sell
Current Market Cap: A$22.33M
Learn more about CDX stock on TipRanks’ Stock Analysis page.